Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
As of close of business last night, Arcutis Biotherapeutics Inc’s stock clocked out at $17.69, up 0.68% from its previous closing price of $17.57. In other words, the price has increased by $0.68 from its previous closing price. On the day, 1.27 million shares were traded. ARQT stock price reached its highest trading level at $17.85 during the session, while it also had its lowest trading level at $17.5.
Ratios:
To gain a deeper understanding of ARQT’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.04 and its Current Ratio is at 3.20. In the meantime, Its Debt-to-Equity ratio is 0.79 whereas as Long-Term Debt/Eq ratio is at 0.79.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Goldman on July 25, 2025, initiated with a Neutral rating and assigned the stock a target price of $18.
On December 30, 2024, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $19. On August 28, 2024, Jefferies started tracking the stock assigning a Buy rating and target price of $15.Jefferies initiated its Buy rating on August 28, 2024, with a $15 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Sep 08 ’25 when Watanabe Todd sold 9,625 shares for $17.54 per share. The transaction valued at 168,799 led to the insider holds 891,944 shares of the business.
Watanabe Todd sold 504 shares of ARQT for $8,829 on Sep 09 ’25. The insider now owns 891,440 shares after completing the transaction at $17.52 per share. On Sep 09 ’25, another insider, Watanabe Todd, who serves as the Officer of the company, bought 504 shares for $17.52 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ARQT now has a Market Capitalization of 2121119488 and an Enterprise Value of 2040460800. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.05 while its Price-to-Book (P/B) ratio in mrq is 15.25. Its current Enterprise Value per Revenue stands at 7.745 whereas that against EBITDA is -25.483.
Stock Price History:
The Beta on a monthly basis for ARQT is 2.04, which has changed by 0.65947473 over the last 52 weeks, in comparison to a change of 0.17089343 over the same period for the S&P500. Over the past 52 weeks, ARQT has reached a high of $18.15, while it has fallen to a 52-week low of $8.03. The 50-Day Moving Average of the stock is 15.15%, while the 200-Day Moving Average is calculated to be 24.25%.
Shares Statistics:
It appears that ARQT traded 1.78M shares on average per day over the past three months and 1825930 shares per day over the past ten days. A total of 119.80M shares are outstanding, with a floating share count of 104.54M. Insiders hold about 12.84% of the company’s shares, while institutions hold 98.63% stake in the company. Shares short for ARQT as of 1756425600 were 17018275 with a Short Ratio of 9.54, compared to 1753920000 on 16637743. Therefore, it implies a Short% of Shares Outstanding of 17018275 and a Short% of Float of 17.53.
Earnings Estimates
The performance of Arcutis Biotherapeutics Inc (ARQT) in the stock market is under the watchful eye of 5.0 analysts actively contributing to its current rating.The consensus estimate for the next quarter is -$0.02, with high estimates of $0.03 and low estimates of -$0.06.
Analysts are recommending an EPS of between -$0.35 and -$0.52 for the fiscal current year, implying an average EPS of -$0.46. EPS for the following year is $0.13, with 6.0 analysts recommending between $0.4 and -$0.21.
Revenue Estimates
In the current quarter, 6 analysts expect revenue to total $86.69M. It ranges from a high estimate of $92M to a low estimate of $83.5M. As of the current estimate, Arcutis Biotherapeutics Inc’s year-ago sales were $44.76MFor the next quarter, 6 analysts are estimating revenue of $98.27M. There is a high estimate of $107.7M for the next quarter, whereas the lowest estimate is $92.28M.
A total of 8 analysts have provided revenue estimates for ARQT’s current fiscal year. The highest revenue estimate was $347M, while the lowest revenue estimate was $323.13M, resulting in an average revenue estimate of $332.31M. In the same quarter a year ago, actual revenue was $196.54MBased on 8 analysts’ estimates, the company’s revenue will be $437.63M in the next fiscal year. The high estimate is $468.4M and the low estimate is $418.84M.
